Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171244 | 0.89 | MAPK14 (0.58) | KDRP2RX3RAF1GSK3BMAPK14 | |
| SCHEMBL16990647 | 0.89 | RAB9A (0.52) | KDRP2RX3RAF1RAB9AGSK3B | |
| SCHEMBL16990602 | 0.88 | MEN1 (0.50) | KDRP2RX3NPC1RAB9AMAPK14 | |
| SCHEMBL15574560 | 0.87 | NPC1 (0.58) | KDRRAF1NPC1RAB9AMAPK14 | |
| SCHEMBL16990607 | 0.86 | MEN1 (0.53) | KDRP2RX3RAF1GSK3BMAPK14 | |
| SCHEMBL16990589 | 0.84 | DDR2 (0.51) | KDRP2RX3RAF1NPC1RAB9A | |
| SCHEMBL16990685 | 0.84 | RAB9A (0.54) | P2RX3RAF1NPC1RAB9AMAPK14 | |
| SCHEMBL13603512 | 0.84 | RAF1 (0.68) | KDRRAF1GSK3BMAPK14MEN1 | |
| SCHEMBL16990596 | 0.83 | DDR2 (0.47) | P2RX3RAF1HTT | |
| SCHEMBL15573350 | 0.82 | P2RX3 (0.44) | P2RX3RAF1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | KDR 404/4885P2RX3 540/4885RAF1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.